Additional file 4: Figure S3. TransCon TLR7/8 Agonist inhibited MC38 tumor growth in a dose-dependent manner. Female C57BL/6 mice were SC implanted with 5 x 105 CT26 tumor cells in their flank. When tumors were grown to a mean tumor volume of ~100 mm3, mice were randomized into treatment cohorts (Day 0; n = 20-22/group). On the same day of randomization, animals received either empty hydrogel (TransCon Vehicle) or 25 or 134 μg (eq. of resiquimod) of TransCon TLR7/8 Agonist as a single intratumoral dose (arrow). Values are represented as mean tumor volume ± SEM. On Day 18, * = p